top of page

Free Biopharma Daily Stock Updates - 02/22/22

$XBI $88.68 | -0.79%

 

Covid Updates

$SRNE -2.5% Sorrento Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses. source



Pipeline Updates

$NCNA -4.6% NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study source


$MRNS -12.8% Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials source


$DCTH -0.5% Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT®. source


$AKBA +8.8% Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch. source


$SUPN -2.1% Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA. source


$ATNM -1.0% Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors. source


$MRNA -0.5% Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data. source


$MORF +3.7% Morphic Presents Positive MORF-057 Data in Oral Presentation at ECCO 2022. source


$GRCL -4.0% Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform. source


$KNSA -0.9% Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration. source


$OTIC +1.0% Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus. source


$BHVN -4.0% Biohaven Enrolls First Patient in Phase 2/3 Sinusitis Trial of Nurtec® ODT. source


$PRVB +1.4% Provention Bio Announces Biologics License Application (BLA) Resubmission for Teplizumab to Address Complete Response Letter (CRL). source


$ADGI +0.2% Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates. source


$BCRX -5.3% BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 for Patients with Renal Complement-mediated Diseases. source


$OYST +5.0% Oyster Point Pharma Announces TYRVAYA™ Nasal Spray Now Covered by Express Scripts. source


$ATHA -0.6% Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease. source


$PSTV -1.0% Plus Therapeutics Partners with Medidata to Apply Innovative Synthetic Control ArmⓇ Solution to Accelerate Brain Cancer Clinical Trial. source


$MNOV -4.1% MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs. source



Business Updates

$OCGN +22.3% Ocugen, Inc. Announces Proposed Public Offering of Common Stock source


 

Posted by FS/JM

0 comments

Commenti


bottom of page